Urology news for Wednesday, November 11, 2026
Top 5 in urology
- FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection FDA action · Urology Times · 2026-11-10
The FDA granted De Novo authorization to the Virtuoso Robotic System, a device intended for robotic resection of bladder tumors.
Why it matters: A new dedicated robotic platform for transurethral bladder tumor resection adds to options for NMIBC management.
More Bladder cancer news - Reconstructed-data analysis: newer BCG-unresponsive NMIBC drugs do not outperform gem/doce Retrospective · Urol Oncol · 2026-11-11
Using reconstructed individual patient data from registration trials, researchers found that none of the FDA-approved BCG-unresponsive NMIBC therapies (nadofaragene, pembrolizumab, nogapendekin alfa inbakicept, TAR-200) showed higher 3-month complete response, durability of response, or disease-free survival than intravesical gemcitabine/docetaxel; gem/doce had higher papillary-cohort DFS than pembrolizumab…
Why it matters: Raises the question of whether gem/doce should remain the benchmark for newer approved agents, though cross-trial, reconstructed-data comparisons limit certainty.
More Bladder cancer news - PSMA-guided salvage surgery shows PSA decline but limited durable cancer control Study · Renal & Urology News · 2026-11-10
A study of PSMA PET-guided salvage lymph node dissection or metastasectomy reported PSA declines in many patients but limited long-term disease control.
Why it matters: Suggests PSMA-guided salvage surgery may offer short-term biochemical benefit without durable oncologic control in recurrent prostate cancer.
More Prostate cancer news - Volumetric ratio may help select children for robotic nephrectomy in Wilms tumor Prospective · Eur Urol Oncol · 2026-11-08
In a prospective single-center series of 60 radical nephrectomies for presumptive Wilms tumor, about 40% (23/60) of children were selected for robot-assisted surgery using a new tumor-to-blood-volume ratio, with no significant difference in oncologic outcomes versus open surgery.
Why it matters: Suggests a volumetric selection criterion could help identify children suitable for robotic nephrectomy in Wilms tumor, pending external validation in larger cohorts.
More Pediatric urology news - SEER-Medicare analysis finds lower urinary adverse events after robotic vs open prostatectomy Retrospective · Transl Androl Urol · 2026-11-08
In a SEER-Medicare cohort of 17,441 beneficiaries aged 66+, robot-assisted radical prostatectomy was associated with lower urinary adverse events than non-robotic approaches (7.7% vs 15.3%), driven mainly by bladder outlet and ureteral obstruction; incontinence rates did not differ, and the association was not detectable beyond 3 years.
Why it matters: Hypothesis generating only; claims-based SEER-Medicare data lack granular surgical and pathologic detail and cannot establish causality for approach selection.
More Prostate cancer news
Prostate cancer news
- Registered trial: phase 3 trial to test perioperative relugolix around radical prostatectomy Trial registered · ClinicalTrials.gov · 2026-11-10
A phase 3 trial will randomize about 268 men with high-risk localized or locally advanced prostate cancer to relugolix before and after radical prostatectomy versus surgery alone followed by relugolix, evaluating this LHRH antagonist in a perioperative role. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-31; planned enrollment 268.
- NICE recommends five AI tools for prostate cancer detection in England Intl regulatory · UKAuthority · 2026-11-10
NICE issued recommendations backing five AI-based software tools to assist detection of prostate cancer, intended for use within the English NHS.
Why it matters: Signals a regulatory pathway for AI-assisted prostate cancer detection that US-based urologists should track.
- Single-arm TULSA study reports 12-month outcomes for localized prostate cancer Phase 1-2 · BJU Int · 2026-11-10
In a single-center phase II study of lesion-targeted transurethral ultrasound ablation in 59 men, 70% were free of in-field grade group 2+ cancer and 52% were free of prostate-wide grade group 2+ cancer at 12 months; no grade 3+ complications occurred within 3 months.
Why it matters: Adds early single-arm safety and efficacy data for a focal ablation technique in localized prostate cancer, but about half had residual clinically significant disease elsewhere in the gland.
- Review catalogs 45 non-cancer factors that can raise or lower PSA levels Review · Prostate · 2026-11-10
A narrative review consolidates 45 benign physiologic, infectious, inflammatory, iatrogenic, hormonal, pharmacologic, and laboratory factors shown to elevate (30 factors) or reduce (15 factors) PSA, including infection, instrumentation, 5-alpha-reductase inhibitors, NSAIDs, statins, and assay variability exceeding 20% between labs.
Why it matters: Offers a practical reference for interpreting borderline PSA results and avoiding unnecessary biopsies driven by false-positive or false-negative PSA elevations or reductions.
- Patient-provider communication quality linked to treatment choice and prostate cancer mortality in cohort study Prospective · JCO Oncol Pract · 2026-11-07
In a population-based cohort of 2,258 Black and White men followed through 2020, higher communication content scores were associated with greater odds of definitive treatment, shorter time to surgery, and lower prostate cancer-specific mortality (sHR 0.78, 95% CI 0.61-0.99).
Why it matters: A long-term cohort study found that men who reported better communication content with their doctors were more likely to get definitive treatment and had lower prostate cancer-specific mortality risk, though this is an…
- Prior cancer history linked to higher germline mutation rates in prostate cancer registry Retrospective · Eur Urol Focus · 2026-11-06
Among 42,645 prostate cancer patients in a germline testing registry, mutation prevalence rose from 10% with no prior cancer to 18% with two or more prior cancers, with the strongest associations seen for prior ureteral, bladder, and colon cancer.
Why it matters: Raises the question of whether a history of additional cancers, rather than family history alone, is associated with germline testing yield in prostate cancer patients.
- CAPItello-281: overall survival results reported for capivasertib in PTEN-deficient mHSPC Study · UroToday · 2026-11-04
Coverage discusses overall survival results from the CAPItello-281 phase 3 trial testing capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, but the specific survival data are not detailed in this item.
Why it matters: PTEN loss defines a molecularly distinct mHSPC subgroup for which targeted AKT inhibition is being tested in a phase 3 trial.
Bladder cancer news
- ANKTIVA plus BCG meets primary endpoint in randomized BCG-naive NMIBC trial RCT · Business Wire · 2026-11-09
The randomized QUILT-2.005 trial of ANKTIVA (nogapendekin alfa inbakicept) added to BCG met its primary endpoint in patients with BCG-naive non-muscle invasive bladder cancer, according to a company announcement; detailed results were not reported.
Why it matters: A positive randomized readout in the BCG-naive setting could expand use of this combination beyond the BCG-unresponsive population already approved.
- Israel approves ANKTIVA plus BCG for BCG-unresponsive NMIBC with CIS Intl regulatory · Business Wire · 2026-11-09
Israel's Ministry of Health approved ANKTIVA (nogapendekin alfa inbakicept) combined with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
Why it matters: Adds another regulatory jurisdiction to the approval already in place in the US for this combination.
- Post hoc THOR analysis links durable tumor response to erdafitinib with longer survival Retrospective · BJU Int · 2026-11-10
A post hoc analysis of the THOR trial found that among erdafitinib-treated patients with FGFR-altered metastatic urothelial carcinoma, those with durable objective response had substantially longer 6-month landmark overall survival than those with non-durable response (HR 8.71).
Why it matters: Suggests response durability, not just objective response rate, may better capture clinical benefit with erdafitinib, though this is a non-prespecified secondary analysis.
- LifeBiotic opens randomized trial of oral botanical LCS103 to prevent NMIBC recurrence Trial opening · LifeBiotic (company press release) · 2026-11-05
Startup LifeBiotic has begun enrolling an open-label randomized trial of LCS103, an oral multi-component herbal formulation, given with standard care for non-muscle invasive bladder cancer. About 60 patients at Rambam Health Care Campus will be assigned 1:1 to one year of LCS103 tablets twice daily plus standard care, or standard care alone, stratified by EAU risk group (NCT07728474).
Why it matters: An early look at a botanical approach to NMIBC recurrence; the primary endpoint is safety, with recurrence and quality of life also tracked.
- Preoperative sarcopenia linked to worse survival after radical cystectomy Retrospective · Clin Genitourin Cancer · 2026-11-07
In a single-center cohort of 320 patients, CT-defined sarcopenia (present in 50%) was independently associated with worse overall survival after radical cystectomy (HR 1.52), though not with major complications or ICU use.
Why it matters: Raises the question of whether CT-based muscle mass assessment could help risk-stratify cystectomy candidates, but is hypothesis generating from a single-center retrospective cohort.
- NICE backs perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer Intl regulatory · pharmaphorum · 2026-11-05
NICE draft guidance recommends pembrolizumab (Keytruda) with enfortumab vedotin (Padcev) before and after cystectomy for muscle-invasive bladder cancer, based on the KEYNOTE-905 and KEYNOTE-B15 trials.
Why it matters: If finalized, NHS patients in England with muscle-invasive bladder cancer gain access to the perioperative regimen.
- Systematic review: BCG-induced granulomatous prostatitis often mimics prostate cancer on MRI Review · World J Urol · 2026-11-06
Across 47 studies, PSA elevation occurred in 54% and PI-RADS 4-5 lesions in 87% of BCG-induced granulomatous prostatitis cases, yet biopsy-confirmed prostate cancer was found in only 7.9%.
Why it matters: Suggests clinicians should consider BCG-induced granulomatous prostatitis in the differential before biopsying suspicious MRI findings in BCG-treated NMIBC patients.
- Postresection urinary tumor DNA sharpens residual disease and recurrence prediction in NMIBC Retrospective · JCO Precis Oncol · 2026-11-06
In 161 NMIBC patients undergoing repeat TURBT, residual tumor was found in 57 (35.4%); adding utDNA to core, expanded, and CIS-augmented indication sets raised AUC for residual tumor detection from 0.544, 0.537, and 0.513 to 0.891, 0.892, and 0.890 respectively, and improved recurrence c-indices from 0.602 to 0.774 (EAU), 0.717 to 0.837 (EORTC), and 0.770 to 0.824 (CUETO).
Why it matters: Suggests utDNA could help refine selection for repeat TURBT and recurrence risk stratification beyond current guideline-based models, pending prospective validation.
Kidney cancer news
- Chinese expert consensus standardizes technique for robot-assisted partial nephrectomy Guideline · Transl Androl Urol · 2026-11-08
A Chinese expert consensus, developed via a three-round Delphi process with GRADE-ADOLOPMENT methodology, addresses ten key clinical questions on patient selection, indications, contraindications, and operative approach (including transperitoneal vs retroperitoneal access) for robot-assisted partial nephrectomy, including expanded use for hilar, endophytic, and complex renal tumors.
Why it matters: Offers a standardized framework from Chinese experts that may inform practice as robotic partial nephrectomy indications expand to more complex tumors.
- Meta-analysis: elevated neutrophil-to-lymphocyte ratio linked to worse survival in RCC Meta-analysis · Transl Androl Urol · 2026-11-08
An updated meta-analysis of 26 cohort studies (6,041 patients) found elevated neutrophil-to-lymphocyte ratio associated with shorter overall, recurrence-free, and disease-free survival in renal cell carcinoma.
Why it matters: Adds support for NLR as a prognostic marker in RCC, though pooled cohort data cannot establish causality or guide individual treatment decisions.
- CD70-targeted PET/CT shows higher sensitivity than PSMA PET for clear cell RCC metastases Prospective · Clin Cancer Res · 2026-11-07
In a retrospective cohort of 128 patients and a prospective head-to-head study of 36 patients, CD70-targeted PET/CT ([68Ga]Ga-NOTA-RCCB6) showed higher sensitivity than PSMA PET ([68Ga]Ga-PSMA-11) for clear cell RCC (88.7% vs 76.1%, P<0.001), especially for lung and liver metastases. Among 26 evaluable patients, CD70 imaging improved lesion detection extent in 35% and changed treatment decisions in 15%.
Why it matters: New imaging data suggest CD70-targeted PET/CT may outperform PSMA PET for detecting clear cell RCC metastases, but findings come from a mixed retrospective/small prospective design and need larger validation.
- Updated prognostic index for renal cell carcinoma brain metastases shows longer survival in contemporary era Retrospective · Lancet Oncol · 2026-11-06
In a 21-institution cohort of 1049 patients with newly diagnosed RCC brain metastases (2016-2022), median overall survival was 20.0 months, roughly double the 9.6 and 12.0 months seen in legacy cohorts from 1985-2015; an updated Renal GPA incorporated performance status, albumin, number of brain metastases, and extracranial disease.
Why it matters: Provides a contemporary, multi-institution benchmark and updated prognostic tool for counseling and trial stratification in RCC patients with brain metastases.
Upper tract urothelial carcinoma news
- Single-port robotic nephroureterectomy via lower anterior access feasible in multicenter series Retrospective · Eur Urol · 2026-11-07
In 47 patients across five centers, single-port retroperitoneal nephroureterectomy with bladder cuff excision via a single extraperitoneal incision achieved 76.7% pentafecta at 12 months, with 6% grade 3+ complications and 15% recurrence at median 12.3-month follow-up.
Why it matters: Describes an emerging single-port surgical technique for UTUC; comparative data against standard approaches are still needed.
- Commentary: pathogenic germline variants in urinary tract cancers are common but often missed Review · Renal & Urology News · 2026-11-04
A commentary piece discusses evidence that pathogenic germline variants are prevalent among patients with urinary tract cancers yet frequently go undetected on standard testing pathways.
Why it matters: Underscores the gap in germline testing uptake in urothelial cancers, consistent with prior reports of low testing rates in UTUC.
- Germline testing performed in under 5% of UTUC patients in claims analysis Retrospective · JCO Oncol Pract · 2026-10-31
A nationwide claims-based analysis of 4,783 patients with newly diagnosed UTUC found only 4.5% underwent germline testing, with no increase from 2015-2023, including just 5.6% of those diagnosed before age 50 who meet guideline criteria.
Why it matters: Raises the question of whether UTUC care pathways are failing to integrate germline evaluation despite guideline endorsement for Lynch syndrome screening; claims data cannot capture reasons testing was not ordered.
- Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27
Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.
Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.
- UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
- TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18
In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).
Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.
- FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15
In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).
Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.
Testicular cancer news
- Testicular cancer incidence concentrated in high-HDI nations, mortality gap widening Study · Urology · 2026-10-28
GLOBOCAN-based analysis of 185 countries found 72,040 new testicular cancer cases and 9,068 deaths in 2022; incidence correlates with national development level while mortality-to-incidence ratio is far higher in lower-HDI regions, with cases projected to rise 22.7% and deaths 40% by 2050.
Why it matters: Highlights persistent global disparities in testicular cancer outcomes tied to treatment access rather than disease biology.
Adrenal tumors news
- Review questions need for universal biochemical workup of adrenal incidentalomas Review · Eur Urol Focus · 2026-11-01
This review argues that routine biochemical testing for pheochromocytoma may be omitted in homogeneous adrenal masses with 10 Hounsfield units or less on unenhanced CT, per 2023 European Society of Endocrinology guidance, while testing for mild autonomous cortisol secretion remains broadly recommended.
Why it matters: Offers a risk-stratified framework for adrenal incidentaloma workup that may reduce unnecessary biochemical testing in low-risk imaging phenotypes.
Penile and urethral cancer news
- Phase 2 trial registered: TROP-2 ADC plus PD-1 inhibitor for advanced penile cancer Trial registered · ClinicalTrials.gov · 2026-10-30
A newly registered single-arm phase 2 trial (SCOPE) plans to evaluate sacituzumab tirumotecan plus toripalimab as chemo-free second-line therapy in platinum-refractory advanced penile squamous cell carcinoma, a setting where current options shrink tumors in only 10-15% of cases. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-01; planned enrollment 31; single site.
Why it matters: Penile cancer has few second-line options; this trial addresses an unmet need with a TROP-2 targeted ADC combination.
Endourology and stone disease news
- Stone-related ED visits before surgery vary by modality, race, and neighborhood vulnerability Retrospective · Urology · 2026-11-09
In an analysis of over 1 million patients from an EHR network, acute stone-related healthcare utilization in the year before definitive surgery was higher before PCNL and lower before SWL versus ureteroscopy, and increased with Black race and higher social vulnerability index, but not rurality.
Why it matters: Raises the question of whether access barriers contribute to acute presentations before definitive stone surgery, warranting prospective evaluation.
- Intelligent vs flexible negative-pressure sheaths show similar stone-free rates after adjustment Retrospective · Transl Androl Urol · 2026-11-08
Combining a 264-patient retrospective cohort with a meta-analysis of 4 studies (539 patients), crude stone-free rates favored intelligent pressure-controlled over flexible negative-pressure ureteral access sheaths, but the difference lost significance after multivariable adjustment and propensity methods.
Why it matters: Raises the question of whether sheath design meaningfully affects stone clearance; retrospective design and attenuation after adjustment limit firm conclusions.
- Suction ureteral access sheaths linked to better stone clearance and fewer infections in RIRS Meta-analysis · World J Urol · 2026-11-06
A meta-analysis of 29 studies (4 randomized, 5604 patients) found suction sheaths reduced residual fragments at early and late follow-up and lowered fever and sepsis rates compared with traditional sheaths, with a possible added benefit from flexible-tip designs.
Why it matters: Adds support for suction-assisted sheaths as a strategy to improve stone clearance and reduce infectious complications in RIRS, though confirmation from randomized trials is needed.
- Meta-analysis of RCTs supports alpha-blockers after shockwave lithotripsy in children Meta-analysis · J Pediatr Urol · 2026-11-06
Pooling 4 randomized trials (408 pediatric patients), adjunctive alpha-1 blockade (tamsulosin or silodosin) after shockwave lithotripsy improved stone-free outcomes compared with placebo or conservative management.
Why it matters: Supports extrapolating adult-guideline adjunctive alpha-blocker use after shockwave lithotripsy to pediatric patients, an area with previously limited pediatric-specific evidence.
- EAU stone risk stratification shows limited accuracy predicting recurrence in large registry analysis Retrospective · BJU Int · 2026-11-06
Using UK Biobank and All of Us data on over 25,000 patients with clinically significant kidney stones, EAU high/low-risk classification predicted 5-year symptomatic recurrence with only modest accuracy (time-dependent AUC 0.61), and decision curve analysis showed no clinical benefit to risk-stratified follow-up.
Why it matters: Is hypothesis generating: raises the question of whether EAU risk stratification criteria need revision, though registry data cannot capture all clinical nuances used in real-world risk assessment.
BPH and male LUTS news
- Phase 2 trial registered testing paclitaxel prostate implant for BPH-related LUTS Trial registered · ClinicalTrials.gov · 2026-11-10
A randomized, double-blind, placebo-controlled phase 2 trial will evaluate RT-310, a paclitaxel prostate implant, for lower urinary tract symptoms due to BPH in about 86 patients. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01; planned enrollment 86.
- New consensus statements issued on minimally invasive BPH surgical treatments Guideline · UroToday · 2026-11-09
A consensus panel issued statements on the role and application of minimally invasive surgical treatments for male LUTS due to benign prostatic enlargement and obstruction.
Why it matters: Offers practical consensus guidance for selecting among MIST options in BPH/LUTS management.
Female pelvic medicine and neurourology news
- Large EHR study finds no higher dementia risk with anticholinergics vs beta-3 agonists for OAB Retrospective · JAMA Netw Open · 2026-11-07
Among 830,393 adults newly treated for overactive bladder using Epic Cosmos data, high-risk anticholinergics were associated with a lower hazard of incident dementia than beta-3 agonists (HR 0.90) or low-risk anticholinergics (HR 0.93).
Why it matters: Raises the question about the presumed cognitive safety advantage of beta-3 agonists over anticholinergics for OAB, but is hypothesis generating from registry data lacking randomization and potential confounding by…
- Urinary incontinence changes linked to falls, functional decline, and depression across global aging cohorts Prospective · Int Urogynecol J · 2026-11-07
In a harmonized analysis of 85,788 older adults from five international cohorts, incident, remitting, and persistent urinary incontinence were each associated with higher odds of falls, ADL decline, and depressive symptoms compared with no incontinence.
Why it matters: Adds support for monitoring functional and mental health trajectories in older adults with any history of urinary incontinence, including those whose symptoms resolve.
- Systematic review compares obliterative vs reconstructive surgery for advanced prolapse in older women Review · Int Urogynecol J · 2026-11-07
A systematic review of 27 study families (29 reports) narratively synthesized comparative data, since heterogeneity precluded pooling. Obliterative surgery was linked to shorter operative time (12/14 comparisons) and lower recurrence-related reoperation (7/8), but overall complications were not consistently lower, and certainty of evidence was low to very low across outcomes.
Why it matters: Supports considering obliterative surgery in select older women, but evidence is from a narrative review of heterogeneous observational studies with low to very low certainty, not a pooled meta-analysis.
Reconstruction and trauma news
- Pump-preserving AUS revision feasible when pump is functioning normally Prospective · Urology · 2026-11-09
In a prospective single-center series of 60 artificial urinary sphincter revisions, surgeons preserved a normally functioning pump in all cases, with no pump-related complications and earlier device reactivation (2 weeks vs standard 6 weeks).
Why it matters: Suggests pump preservation may be a feasible option in selected AUS revisions to limit scrotal dissection and shorten reactivation time.
- Allium covered stents beat Memokath for radiation ureteral strictures but carry unique fistula risk Retrospective · World J Urol · 2026-11-09
Among 149 patients (205 ureteral units) treated for radiation-induced ureteral strictures, Allium stents showed higher 12- and 36-month primary success (75.9% vs 49.3% and 33.2% vs 23.2%) and cumulative success (96.3% vs 91.5% at 12 months, 64.0% vs 28.2% at 36 months) compared with Memokath stents, with median primary success duration of 30 vs 12 months (log-rank P < 0.001); ureteral fistulas occurred in 11 patients, exclusively in the Allium group.
Why it matters: For refractory radiation strictures, covered self-expandable stents may offer meaningfully longer patency than thermo-expandable stents, though the fistula signal tied to larger caliber and tandem stenting warrants careful sizing and patient selection.
- Meta-analysis: urethroplasty for post-BPH surgery bulbomembranous strictures shows 90% pooled patency Meta-analysis · BJU Int · 2026-11-01
A systematic review and meta-analysis of 417 patients from 9 observational studies found an overall pooled patency rate of 90% for urethroplasty after bulbomembranous strictures following BPH surgery, with patency around 87-94% depending on technique, though definitions of patency and continence varied widely.
Why it matters: Provides pooled benchmark patency rates for a challenging post-BPH stricture population, though heterogeneous outcome definitions and moderate-to-serious risk of bias limit certainty.
- Retrospective series reports outcomes after revision of difficult-to-catheterize continent channels Retrospective · Neurourol Urodyn · 2026-10-29
In a single-institution retrospective review of 45 adults undergoing 54 continent catheterizable channel revisions, 76% were free from reoperation at median 46-month follow-up, with success rates similar across suprafascial, subfascial, and replacement techniques.
Why it matters: Is hypothesis generating for channel revision technique selection given single-center retrospective design without randomized comparison.
- Meta-analysis: PAMORAs linked to faster bowel recovery after radical cystectomy Meta-analysis · Transl Androl Urol · 2026-10-14
A systematic review and meta-analysis found that adding peripherally acting mu-opioid receptor antagonists (alvimopan, naloxegol, methylnaltrexone) to enhanced recovery pathways after radical cystectomy was associated with shortened time to first flatus and improved postoperative GI recovery versus enhanced recovery alone, though certainty of evidence varied and data specific to cystectomy remain limited and…
Why it matters: Suggests PAMORAs may help reduce postoperative ileus after cystectomy, but evidence quality is variable and more robust data are needed before routine incorporation into enhanced recovery protocols.
Men's health news
- AI-assisted microdissection TESE linked to higher sperm retrieval and live birth rates in azoospermia Retrospective · Asian J Androl · 2026-11-07
In a retrospective cohort of 1,286 men with non-obstructive azoospermia, AI-assisted micro-TESE was associated with higher sperm retrieval rate (68.1% vs 47.6%) than conventional surgery, with improvements also seen in ICSI fertilization, pregnancy, and live birth rates.
Why it matters: Suggests AI-assisted intraoperative guidance during micro-TESE may be associated with improved sperm retrieval, but comparative design and lack of randomization limit causal interpretation.
- Multimodal infection-prevention protocol tied to very low infection rate in penile prosthesis surgery Retrospective · Urology · 2026-11-07
A structured perioperative protocol (MRSA decolonization, no-touch technique, antibiotic irrigation, compressive dressing) across 487 inflatable penile prosthesis procedures was associated with an overall infection rate of 0.21%.
Why it matters: Suggests a bundled infection-prevention approach may be associated with very low infection rates in penile implant surgery, though single-surgeon design limits generalizability.
Pediatric urology news
- Review outlines when genetic testing is useful in CAKUT for urologists Review · Eur Urol Focus · 2026-11-08
A review discusses when genetic evaluation adds value in congenital anomalies of the kidney and urinary tract, emphasizing bilateral or severe anomalies, syndromic features, familial disease, and anatomy-function mismatch, while noting genetics should not drive surgical decisions alone.
- First multicentre study of Versius robot in pediatric urology reports interim safety data Prospective · J Pediatr Urol · 2026-11-06
In 60 procedures (mostly pyeloplasty) across three UK centres, 98.3% were completed robotically with one open conversion and no transfusions; median operative time was 195.5 minutes.
Why it matters: Early prospective data suggest the Versius platform may be feasible for pediatric minimally invasive urology, pending larger follow-up.
- Low-level pyuria tied to large jump in antibiotic prescribing for suspected pediatric UTI Retrospective · Pediatrics · 2026-11-06
Among 1150 pediatric ambulatory visits with urinalysis, 191 (16.6%) patients received antibiotics, and trace-to-low pyuria was associated with empiric antibiotic initiation (adjusted OR 6.62, 95% CI 3.72-11.79) versus no pyuria. This level of pyuria accounted for an adjusted attributable fraction of 17.0% (95% CI 10.3%-23.2%) for overtreatment in culture-negative children, compared with only 1.8% (95% CI 1.1%-2.4%) attributable fraction for treatment of culture-confirmed UTI.
Why it matters: Suggests that weighing degree of pyuria alongside age, symptoms, and risk factors rather than treating any pyuria as definitive could help reduce unnecessary antibiotic exposure in children evaluated for UTI.
- Thermocautery circumcision linked to far fewer early complications than bipolar sleeve or scalpel Retrospective · J Pediatr Urol · 2026-11-06
In a frequency-matched retrospective cohort of 31,100 boys, thermocautery guillotine circumcision had a complication rate of 0.6% versus 8.68% (bipolar sleeve) and 7.21% (scalpel guillotine), with zero bleeding events requiring suture ligation versus 15 and 25 respectively.
Why it matters: Raises the question of whether thermocautery technique reduces early circumcision complications, though retrospective design and single-center practice patterns limit causal inference.
- Nearly half of retractile testes ascend or need orchiopexy by age 7 in cohort study Prospective · J Urol · 2026-11-04
In a prospective single-institution cohort of 237 boys with retractile testicle(s) followed to median 7 years, cumulative incidence of testicular ascent was 47% and of orchiopexy was 57% by 84 months, with lower BMI and right-sided laterality associated with ascent.
Why it matters: Suggests boys with retractile testes warrant longer-term surveillance by a pediatric urologist rather than single-visit reassurance.
- New expert consensus aims to standardize surgery for pediatric kidney cancer Guideline · citybuzz - · 2026-11-03
A new expert consensus statement seeks to standardize surgical approach for childhood kidney cancer, according to the report.
Why it matters: A consensus statement may help reduce variability in surgical management of pediatric renal tumors.
- Multidisciplinary review addresses undescended testis management in medically complex children Review · J Urol · 2026-10-29
A narrative review by specialists across anesthesia, genetics, oncology, and urology examines how standard orchiopexy timing recommendations for undescended testis may need individualized reconsideration in children with syndromic or developmental conditions given elevated surgical risk.
Why it matters: Offers a framework for weighing surgical and anesthetic risk against fertility and oncologic benefit when managing undescended testis in medically complex children.
- AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16
The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.
Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.
Technology and AI news
- Gemini and ChatGPT outperform Claude in matching expert consensus on prostate cancer guideline questions Study · UroToday · 2026-11-09
In a two-round Delphi study, 11 experts evaluated 25 guideline-based prostate cancer questions answered by three LLMs: consensus agreement was reached for 23/25 (92%) Gemini responses, 20/25 (80%) ChatGPT responses, and 14/25 (56%) Claude responses (p=0.0033), with explicit disagreement noted for 3 Claude answers after round two.
Why it matters: Suggests LLMs like Gemini and ChatGPT may assist in interpreting routine guideline content but require expert oversight, with notably lower reliability from Claude, especially in complex scenarios involving advanced imaging or genetic testing.
More urology news
- Registered trial: phase 2 trial tests neoadjuvant toripalimab/lenvatinib +/- SBRT in non-clear cell RCC Trial registered · ClinicalTrials.gov · 2026-11-06
A single-center, nonrandomized phase 2 study will enroll about 36 patients with resectable, locally advanced non-clear cell RCC to receive neoadjuvant toripalimab plus lenvatinib with or without SBRT before surgery, with tumor necrosis percentage as the primary outcome. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2026-11-10; planned enrollment 36.
- Registered trial: phase 2 trial of neoadjuvant pucotenlimab, lenvatinib and SBRT for technically difficult clear cell RCC Trial registered · ClinicalTrials.gov · 2026-11-06
A single-arm phase 2 trial will enroll about 24 adults with localized clear cell RCC that is a technically difficult candidate for partial nephrectomy, testing neoadjuvant pucotenlimab, lenvatinib and SBRT before surgery with objective response rate as the primary endpoint. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2026-11-10; planned enrollment 24.
- Delphi study defines 15 core entrustable professional activities for urology residency graduates Study · Urology · 2026-10-16
A national Delphi panel of academic urology educators distilled 242 candidate activities into 15 core EPAs that urology residents should perform independently by graduation, covering evaluation, medical management, and a narrower set of procedures.
Why it matters: Provides a competency-based framework that may inform future resident assessment and milestone evaluation in urology training programs.
Loading today's edition…